177 terminated. 177 Phase 3, 23 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 177 | Terminated 177 |
| Phase 2 | 23 | Terminated 23 |
Follow Autoimmune Diseases: new trials by email Literature Review of Autoimmune Diseases trials Research Report on Autoimmune Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease. Efgartigimod PH20 SC, Placebo PH20 SC - Thyroid Eye Disease | Phase 3 | Terminated | argenx | 105 | 2024-03-28 | 2026-03-16 |
| Long-Term Voclosporin Treatment in Adolescent and Pediatric Subjects With Lupus Nephritis voclosporin - Adolescent Lupus Nephritis, Pediatric Lupus Nephritis | Phase 3 | Terminated | Aurinia Pharmaceuticals Inc. | 4 | 2024-03-28 | 2026-02-10 |
| A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease Efgartigimod PH20 SC, Placebo PH20 SC - Thyroid Eye Disease | Phase 3 | Terminated | argenx | 102 | 2024-03-27 | 2026-03-16 |
| Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis Voclosporin, Placebo Oral Capsule - Adolescent Lupus Nephritis, Pediatric Lupus Nephritis | Phase 3 | Terminated | Aurinia Pharmaceuticals Inc. | 9 | 2023-10-10 | 2026-02-10 |
| A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid efgartigimod PH20 SC, Prednisone - Bullous Pemphigoid | Phase 3 | Terminated | argenx | 64 | 2023-03-22 | 2026-02-25 |
| A Study With Imlifidase in Anti-GBM Disease Imlifidase, Plasma exchange (PLEX), Cyclophosphamide (CYC) - Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease | Phase 3 | Terminated | Hansa Biopharma AB | 50 | 2022-12-22 | 2026-03-04 |
| Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease Observational cohort study, Batoclimab - Thyroid Eye Disease | Phase 3 | Terminated | Immunovant Sciences GmbH | 109 | 2022-11-06 | 2026-04-29 |
| Clemastine Fumarate as Remyelinating Treatment in Internuclear Ophthalmoparesis and Multiple Sclerosis Clemastine Fumarate, Placebo - Multiple Sclerosis, Internuclear Ophthalmoplegia | Phase 3 | Terminated | Amsterdam UMC, location VUmc | 47 | 2022-08-30 | 2026-05-06 |
| Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis Secukinumab - Lupus Nephritis | Phase 3 | Terminated | Novartis Pharmaceuticals | 31 | 2022-08-22 | 2025-05-16 |
| Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis Batoclimab 680 mg SC weekly, Batoclimab 340 mg SC weekly, Matching Placebo SC - Generalized Myasthenia Gravis | Phase 3 | Terminated | Immunovant Sciences GmbH | 233 | 2022-06-27 | 2026-09-14 |
| A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1) Telitacicept, Placebo - Systemic Lupus Erythematosus | Phase 3 | Terminated | Vor Biopharma | 91 | 2022-06-20 | 2026-01-09 |
| A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Colecalciferol 2000 IU, Placebo - Type 1 Diabetes Mellitus | Phase 3 | Terminated | Diamyd Medical AB | 321 | 2022-05-19 | 2026-08-26 |
| A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis Natalizumab - Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Terminated | Biogen | 21 | 2022-04-26 | 2025-11-25 |
| Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA TC99m-tilmanocept - Rheumatoid Arthritis | Phase 3 | Terminated | Navidea Biopharmaceuticals | 169 | 2022-03-02 | 2025-01-23 |
| Efficacy and Safety of Tolebrutinib (SAR442168) Tablets in Adult Participants With Generalized Myasthenia Gravis Tolebrutininb, Placebo - Myasthenia Gravis | Phase 3 | Terminated | Sanofi | 6 | 2021-12-03 | 2025-09-09 |
| A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED) Secukinumab, Placebo - Thyroid Eye Disease, Graves Orbitopathy | Phase 3 | Terminated | Novartis Pharmaceuticals | 28 | 2021-11-29 | 2026-04-15 |
| Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis Mayzent, Ocrevus - Secondary-progressive Multiple Sclerosis | Phase 2 / Phase 3 | Terminated | State University of New York at Buffalo | 8 | 2021-11-13 | 2025-05-13 |
| Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity Phase 2; Low Dose MYOBLOC (10,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 2; Placebo - Spasticity, Cerebrovascular Accident | Phase 2 / Phase 3 | Terminated | Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC | 32 | 2021-11-02 | 2026-05-27 |
| A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis Satralizumab, Placebo - Generalized Myasthenia Gravis | Phase 3 | Terminated | Hoffmann-La Roche | 188 | 2021-10-19 | 2025-02-28 |
| Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis Nabiximols, Placebo - Spasticity With Multiple Sclerosis | Phase 3 | Terminated | Jazz Pharmaceuticals | 56 | 2021-08-16 | 2024-12-11 |
Showing 20 of 177. Sign in to see all of them.
Arthritis, Rheumatoid (31) · Multiple Sclerosis (28) · Diabetes Mellitus, Type 1 (23) · Lupus Erythematosus, Systemic (22) · Lupus Nephritis (15) · Multiple Sclerosis, Relapsing-Remitting (14) · Diabetes Mellitus (10) · Arthritis, Juvenile (8) · Multiple Sclerosis, Chronic Progressive (8) · Diabetes Mellitus, Type 2 (7) · Nephritis (6) · Myasthenia Gravis (5) · Purpura, Thrombocytopenic, Idiopathic (5) · Recurrence (5)
Immune System Diseases (175) · Skin and Connective Tissue Diseases (83) · Connective Tissue Diseases (68) · Nervous System Diseases (61) · Autoimmune Diseases of the Nervous System (56) · Demyelinating Autoimmune Diseases, CNS (46) · Demyelinating Diseases (46) · Musculoskeletal Diseases (45) · Pathological Conditions, Signs and Symptoms (41) · Joint Diseases (38) · Rheumatic Diseases (38) · Arthritis (36) · Pathologic Processes (31) · Endocrine System Diseases (29)
Methotrexate (14) · Prednisone (13) · Mycophenolic Acid (12) · Cyclophosphamide (8) · Methylprednisolone (8) · ocrelizumab (8) · Azathioprine (7) · Prednisolone (6) · tabalumab (6) · Adrenal Cortex Hormones (5) · Insulin Aspart (5) · Rituximab (5) · Glatiramer Acetate (4) · Insulin (4) · Interferon beta-1a (4)
Biogen (10) · Eli Lilly and Company (9) · Novartis Pharmaceuticals (9) · Genentech, Inc. (7) · GlaxoSmithKline (6) · Hoffmann-La Roche (6) · argenx (4) · Mannkind Corporation (3) · Novo Nordisk A/S (3) · Pfizer (3) · Sanofi (3) · UCB Biopharma SRL (3) · UCB Pharma (3) · Alexion Pharmaceuticals, Inc. (2) · Amgen (2)
United States (112) · Spain (61) · Germany (59) · Poland (55) · United Kingdom (52) · Italy (50) · Canada (43) · Hungary (41) · Czechia (40) · Australia (38) · France (38) · Argentina (33) · Russia (31) · Belgium (29) · Japan (29)
Wolfgang Dummer, M.D. (3) · Anna Barry (2) · Gilbert Wagener, MD (2)
PMID 33687069, PMID 24498318, PMID 34376508, PMID 38299639, PMID 41092316, PMID 11824975, PMID 15803929, PMID 15968009, PMID 18163506, PMID 19847907, PMID 20737510, PMID 20737514, PMID 21060104, PMID 21325604, PMID 21503695, PMID 21905001, PMID 22296077, PMID 22325903, PMID 22389919, PMID 22791906, PMID 22806274, PMID 23252526, PMID 2334081, PMID 23462431, PMID 23529285, PMID 23570538, PMID 23615499, PMID 24254965, PMID 24302596, PMID 24504810, PMID 24898925, PMID 25873635, PMID 26009577, PMID 26314396, PMID 26535134, PMID 26827074, PMID 26835147, PMID 26867033, PMID 27411694, PMID 28115015, PMID 28357504, PMID 28507219, PMID 28592297, PMID 28639937, PMID 28856176, PMID 29545067, PMID 29560379, PMID 29654485, PMID 30002145, PMID 30269054
2019 (6), 2017 (4), 2018 (4), 2014 (3), 2016 (3), 2023 (3), 2005 (2), 2009 (2), 2008 (1), 2015 (1), R01HD066139 (1), U01AR042540 (1), U01DC003209 (1), U01DK071733 (1), U01HL072268 (1)